Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medical Therapy of Prostatic Symptoms (MTOPS)
NCT00021814Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 1995
- Primary completion
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of finasteride and doxazosin in benign prostatic hyperplasia (BPH) (4 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Time to overall clinical progression of benign prostatic hyperplasia at 4.5 years. Started Dec 1995; status: completed.
02
Drugs
finasteridedoxazosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00021814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021814.